For millions of women living with what has long been known as polycystic ovary syndrome, the condition’s name has often felt incomplete, misleading, and at times dismissive. Now, after more than a decade of international debate and research, global medical experts have officially announced that PCOS will be renamed polyendocrine metabolic ovarian syndrome, or PMOS, beginning with a global transition rollout in 2026 and full implementation expected by 2028. Researchers and patient advocates say the shift reflects a broader understanding of a disease that affects far more than the ovaries and has historically left many women, particularly women of color, underdiagnosed and underserved. (Healthline)

The name change was unveiled this week following a global consensus process involving more than 22,000 patients, clinicians, and researchers, with findings published in The Lancet and presented at the European Congress of Endocrinology. Health organizations involved in the effort said the old term “polycystic ovary syndrome” incorrectly centered ovarian cysts, even though many patients never develop cysts at all. Experts say the terminology contributed to years of confusion, delayed diagnoses, fragmented care, and stigma surrounding a condition that affects an estimated 170 million women worldwide. (Endocrine Society)

The new name, polyendocrine metabolic ovarian syndrome, is intended to better reflect the disorder’s full-body impact. PMOS is increasingly understood as a complex endocrine and metabolic condition linked to insulin resistance, cardiovascular disease, infertility, chronic inflammation, anxiety, depression, and increased risks of Type 2 diabetes. Researchers say the previous focus on reproduction alone often minimized the condition’s long-term health consequences. (Healthline)

For many women, particularly Black, Latina, Indigenous, and South Asian women, the announcement also highlights longstanding inequities in women’s healthcare. Studies have shown that women of color frequently face delayed diagnoses and reduced access to specialty care for hormonal and metabolic disorders. Some researchers say those disparities are rooted in a broader history of medical racism and the historic dismissal of women’s pain and symptoms in healthcare settings.

The story of PMOS is closely tied to that history. For decades, women reporting symptoms such as irregular periods, unexplained weight gain, chronic fatigue, infertility, excessive hair growth, acne, or insulin resistance were often told to simply lose weight or manage stress rather than receive comprehensive hormonal testing. Advocates say the outdated name reinforced misconceptions that the disorder was only reproductive or cosmetic in nature, making it harder for patients to be taken seriously.

The conversation has resonated strongly online, where many patients welcomed the change while also expressing frustration that awareness and treatment options have lagged for years. On Reddit and other patient forums, women described years of being ignored by healthcare providers before finally receiving diagnoses. Others said the new terminology validates experiences that extended far beyond fertility struggles. (Reddit)

Those frustrations mirror broader concerns in women’s health research. Historically, conditions primarily affecting women have received less funding and scientific attention than many other chronic diseases. Researchers say women of color have been especially overlooked in clinical studies despite facing higher rates of metabolic disease, obesity-related complications, and barriers to preventative healthcare.

The condition’s metabolic component is particularly important for minority communities already disproportionately affected by diabetes and cardiovascular disease. According to experts involved in the PMOS renaming process, insulin resistance is one of the central drivers of the disorder, yet it was often overshadowed under the old name. By including the word “metabolic,” researchers hope physicians will better recognize the condition’s links to long-term chronic illness and intervene earlier. (Healthline)

Doctors and advocates say the new terminology could also reduce stigma. The phrase “polycystic ovaries” frequently caused confusion and anxiety among patients who believed they had dangerous cysts or reproductive abnormalities. Some women reported feeling that their symptoms were dismissed if ultrasounds did not show cysts, despite meeting other diagnostic criteria. Experts say the updated name more accurately reflects the hormonal and endocrine dysfunction underlying the condition. (Medical News Today)

Still, many patients say a name change alone will not fix the systemic problems surrounding women’s healthcare. Advocates continue to call for more research funding, expanded insurance coverage, earlier screenings, and culturally competent care for communities disproportionately impacted by chronic hormonal and metabolic disorders. Some physicians also warn that public education will be critical during the transition period to avoid confusion among patients already familiar with the term PCOS.

For many women living with PMOS, the announcement represents both progress and a reminder of how long the medical system has struggled to fully understand their experiences. As healthcare organizations prepare to adopt the new terminology over the next several years, experts say the larger challenge will be ensuring that the attention surrounding the name change leads to meaningful improvements in diagnosis, treatment, and equity in women’s health care worldwide. (Endocrine Society)